The markets closed lower with the Dow losing 31 points to 17,685 ahead of the March payrolls report tomorrow. Nasdaq held steady at 4,869.
On the upside
Genocea Biosciences (Nasdaq: GNCA) reported positive 12-month efficacy data from a Phase 2 trial of GEN-003 to treat genital herpes.
Reuters reported that Medivation (Nasdaq: MDVN) engaged in discussions with JPMorgan Chase to explore a possible sale of the company.
Sky Solar Holdings (Nasdaq: SKYS) narrowed losses for the fourth quarter as revenue soared.
On the downside
aTyr Pharma (Nasdaq: LIFE) widened losses as expenses surged.
Anacor Pharmaceuticals (Nasdaq: ANAC) will offer $250 million in convertible senior notes.
Silver Wheaton (NYSE: SLW) entered a $500 million bought deal financing with RBC Capital Markets, BMO Capital Markets, CBIC Capital Markets and Scotiabank.
In the broad market, advancing issues outpaced decliners by a margin of nearly 3 to 2 on the NYSE and by more than 9 to 7 on Nasdaq. The broader S&P 500 lost 4 points to 2,059. Bitcoin added $2 to $415.
